Cargando…

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

BACKGROUND: Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited. METHODS: We conducted a systematic review of published studies reporting the efficacy of favipiravir against C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manabe, Toshie, Kambayashi, Dan, Akatsu, Hiroyasu, Kudo, Koichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159019/ https://www.ncbi.nlm.nih.gov/pubmed/34044777 http://dx.doi.org/10.1186/s12879-021-06164-x

Ejemplares similares

Trends in clinical features of novel coronavirus disease (COVID-19): A systematic review and meta-analysis of studies published from December 2019 to February 2020
por: Manabe, Toshie, et al.
Publicado: (2020)

Pneumonia-associated death in patients with dementia: A systematic review and meta-analysis
por: Manabe, Toshie, et al.
Publicado: (2019)

Knowledge, Attitudes, and Practices Survey among Nursing Care Workers Involved in Caring for Older Adults during the Early Stage of the COVID-19 Pandemic in Japan
por: Kambayashi, Dan, et al.
Publicado: (2022)

Adaptations in the role of pharmacists under the conditions of the COVID-19 pandemic: a systematic review and meta-analysis
por: Kambayashi, Dan, et al.
Publicado: (2023)

Effect of asthma, COPD, and ACO on COVID-19: A systematic review and meta-analysis
por: Uruma, Yuka, et al.
Publicado: (2022)

Factors Associated with Pneumonia-caused Death in Older Adults with Autopsy-confirmed Dementia
por: Manabe, Toshie, et al.
Publicado: (2017)

Spatiotemporal distribution of COVID-19 during the first 7 months of the epidemic in Vietnam
por: Manabe, Toshie, et al.
Publicado: (2021)

Prognostic Factors Related to Dementia with Lewy Bodies Complicated with Pneumonia: An Autopsy Study
por: Manabe, Toshie, et al.
Publicado: (2016)

Knowledge, attitudes, and practices regarding COVID-19 among pharmacists partnering with community residents: A national survey in Japan
por: Kambayashi, Dan, et al.
Publicado: (2021)

The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
por: Hassanipour, Soheil, et al.
Publicado: (2021)

Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
por: Hassanipour, Soheil, et al.
Publicado: (2022)

Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients
por: Prakash, Ajay, et al.
Publicado: (2020)

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
por: Shrestha, Dhan Bahadur, et al.
Publicado: (2020)

Seasonality of newly notified pulmonary tuberculosis in Japan, 2007–2015
por: Manabe, Toshie, et al.
Publicado: (2019)

Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)

Effectiveness of favipiravir in COVID-19: a live systematic review
por: Özlüşen, Batu, et al.
Publicado: (2021)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
por: Qomara, Windi Fresha, et al.
Publicado: (2021)

Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials
por: Arab-Zozani, Morteza, et al.
Publicado: (2020)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies()
por: Hung, Dang The, et al.
Publicado: (2022)

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
por: Pilkington, Victoria, et al.
Publicado: (2020)

Favipiravir for COVID-19 in a Patient on Hemodialysis
por: Hirai, Daisuke, et al.
Publicado: (2021)

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Evaluation of the effect of favipiravir on patients with COVID-19
por: Kamali, Alireza, et al.
Publicado: (2023)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()
por: Cai, Qingxian, et al.
Publicado: (2020)

Effect of Ankle Weights as a Frailty Prevention Strategy in the Community-Dwelling Elderly: A Preliminary Report
por: Akatsu, Hiroyasu, et al.
Publicado: (2022)

Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19
por: Ison, Michael G., et al.
Publicado: (2021)

Regional trends in the use of steroids and favipiravir for COVID-19 treatment
por: Asai, Yusuke, et al.
Publicado: (2023)

An economical and practical procedure of favipiravir synthesis for the treatment of Covid-19
por: Karatas, Hacer, et al.
Publicado: (2022)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Future of antivirals in COVID-19: The case of favipiravir
por: Kow, Chia Siang, et al.
Publicado: (2022)

Efficacy and Safety of Favipiravir in Treating COVID-19 Patients: A Meta-Analysis of Randomized Control Trials
por: Batool, Saima, et al.
Publicado: (2023)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
por: Irie, Kei, et al.
Publicado: (2020)

Favipiravir exposure and pregnancy outcome of COVID-19 patients
por: Tırmıkçıoğlu, Zeynep
Publicado: (2022)

Polymyxin-B-immobilized-fiber column hemoperfusion with oseltamivir treatment for ARDS due to influenza H1N1/09
por: Binh, Nguyen Gia, et al.
Publicado: (2015)

1147. Regional Trends in Favipiravir and Steroid Use in the Treatment of COVID-19
por: Asai, Yusuke, et al.
Publicado: (2022)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient
por: Tawara, Junsuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9nh0kgbdmjhgd2eu9vt8bl6bio